# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

> **NCT06342713** · PHASE1 · RECRUITING · sponsor: **BeiGene** · enrollment: 211 (estimated)

## Conditions studied

- Healthy Participants
- Healthy Subjects
- Healthy Volunteers
- Autoimmune Diseases
- Healthy Adult Participants
- Atopic Dermatitis
- Prurigo Nodularis

## Interventions

- **DRUG:** BGB-45035
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06342713
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2026-05-23
- **Final completion:** 2026-05-23
- **Target enrollment:** 211 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342713, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06342713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*